Merck's LIPFENDRA Approved as First Oral PCSK9 Inhibitor for Hypercholesterolemia
LIPFENDRA (enlicitide) is the first FDA-approved oral PCSK9 inhibitor, significantly reducing LDL-C by up to 59%.
Therapeutic Area
Therapeutic area intelligence for Hypercholesterolemia with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.